Division of Pediatric Urology, Morgan Stanley Children's Hospital of New York-Presbyterian, New York, New York, USA.
J Urol. 2010 Feb;183(2):724-30. doi: 10.1016/j.juro.2009.10.032. Epub 2009 Dec 21.
Primary bladder neck dysfunction is a nonneurogenic voiding disorder frequently overlooked in pediatrics. The diagnosis classically is made by videourodynamics but can also be made with noninvasive uroflow studies with pelvic floor electromyography. We report our long-term results using alpha-blocker therapy in patients with primary bladder neck dysfunction.
We reviewed 51 neurologically normal children (mean age 11.6 years, range 3.5 to 17.8) meeting criteria for primary bladder neck dysfunction who underwent alpha-blocker therapy for at least 1 year. All patients were symptomatic with abnormal flow parameters and an electromyogram lag time of 6 seconds or more on initial uroflow/electromyography. Pretreatment and on-treatment uroflow/electromyogram studies were performed in all patients. Average and maximum uroflow rates, electromyogram lag times and post-void residual volumes were compared.
After a mean followup of 46.2 months (range 12 to 124) mean average and maximum uroflow rates improved from 7.0 to 12.4 cc per second and from 12.4 to 20.3 cc per second, respectively, while mean electromyogram lag time decreased from 30.8 to 5.8 seconds (all p <0.01). Of the patients 85% reported subjective symptomatic relief. A total of 15 patients (29%) stopped alpha-blocker therapy for various reasons, none related to side effects. Repeat off-treatment uroflow/electromyogram studies showed that measured parameters reverted to pretreatment values (all p <0.05). Eight of these 15 patients eventually resumed alpha-blocker therapy, while only 3 remained asymptomatic off of the alpha-blocker.
alpha-Blocker therapy continues to benefit children with primary bladder neck dysfunction even after 3 years of treatment. Few patients can come off of alpha-blocker therapy without returning to their pretreatment state, suggesting the condition is likely chronic in most patients.
原发性膀胱颈功能障碍是一种常见于儿科的非神经源性排尿障碍,常被忽视。该诊断经典地通过尿动力学检查做出,但也可以通过非侵入性尿流研究结合盆底肌电图进行诊断。我们报告了使用α受体阻滞剂治疗原发性膀胱颈功能障碍患者的长期结果。
我们回顾了 51 例符合原发性膀胱颈功能障碍标准的神经正常儿童(平均年龄 11.6 岁,范围 3.5 至 17.8 岁),他们接受了至少 1 年的α受体阻滞剂治疗。所有患者均有症状,表现为异常的流量参数和初始尿流/肌电图上的肌电图滞后时间超过 6 秒。所有患者均进行了治疗前和治疗后的尿流/肌电图研究。比较了平均和最大尿流率、肌电图滞后时间和残余尿量。
平均随访 46.2 个月(范围 12 至 124 个月)后,平均平均和最大尿流率分别从 7.0 增加到 12.4 cc/秒和从 12.4 增加到 20.3 cc/秒,而平均肌电图滞后时间从 30.8 减少到 5.8 秒(均 p<0.01)。85%的患者报告有主观症状缓解。共有 15 名患者(29%)因各种原因停止了α受体阻滞剂治疗,没有与副作用相关的原因。再次停止治疗后的尿流/肌电图研究显示,测量参数恢复到治疗前的值(均 p<0.05)。这 15 名患者中的 8 名最终恢复了α受体阻滞剂治疗,而只有 3 名患者在停止治疗后仍无症状。
即使经过 3 年的治疗,α受体阻滞剂治疗仍能使原发性膀胱颈功能障碍的儿童受益。很少有患者可以在不恢复到治疗前状态的情况下停止使用α受体阻滞剂治疗,这表明大多数患者的病情可能是慢性的。